Page 268 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Chapter 10
15. Zhou ZW, Wang GQ, Wan de S, et al. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. Chemotherapy. 2007;53(2):127-131.
16. Jiang H, Lu J, Jiang J, Hu P. Important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 2004;44(11):1260-1272.
17. Boisdron-Celle M, Remaud G, Traore S, et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer letters. 2007;249(2):271-282.
18. Kristensen MH, Pedersen P, Mejer J. The value of dihydrouracil/uracil plasma ratios in predicting 5-fluorouracilrelated toxicity in colorectal cancer patients. J Int Med Res. 2010;38(4):1313-1323.
19. Wettergren Y, Carlsson G, Odin E, Gustavsson B. Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant
5-fluorouracil-based chemotherapy. Cancer. 2012;118(11):2935-2943.
20. Meulendijks D, Henricks LM, Jacobs BAW, et al. Pretreatment serum uracil concentration as a
predictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer. 2017;116(11):1415-
1424.
21. van Staveren MC, van Kuilenburg ABP, Guchelaar HJ, et al. Evaluation of an oral uracil loading
test to identify DPD-deficient patients using a limited sampling strategy. Br J Clin Pharmacol.
2016;81(3):553-561.
22. van Staveren MC, Theeuwes-Oonk B, Guchelaar HJ, Van Kuilenburg ABP, Maring JG.
Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency. Cancer Chemother Pharmacol. 2011;68(6):1611- 1617.
23. Mattison LK, Fourie J, Hirao Y, et al. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2- 13C]dihydrouracil. Clin Cancer Res. 2006;12(2):549-555.
24. Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clinical Cancer Research. 2006;12(18):5491-5495.
25. Mattison LK, Ezzeldin H, Carpenter M, Modak A, Johnson MR, Diasio RB. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res. 2004;10(8):2652-2658.
26. Thomas HR, Ezzeldin HH, Guarcello V, Mattison LK, Fridley BL, Diasio RB. Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism. Pharmacogenet Genomics. 2007;17(11):973-987.
27. Saif MW, Syrigos K, Mehra R, Mattison LK, Diasio RB. Dihydropyrimidine dehydrogenase deficiency (DPD) in GI malignancies: Experience of 4-years. Pak J Med Sci. 2007;23(6):832-839.
28. van Staveren MC, Guchelaar HJ, van Kuilenburg ABP, Gelderblom H, Maring JG. Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency. Pharmacogenomics J. 2013;13(5):389-395.
266